Introduction
The ability of blood borne cells to perform their designated biological function(s) requires cell surface adhesion molecules to engage counter-receptors at the appropriate time and location. For example, platelets and von Willebrand factor (VWF) co-exist in circulating blood and must interact at sites of arterial injury in order to promote effective hemostasis. This process is triggered upon the binding of plasma VWF to exposed components of the injured vessel wall where it can then initiate the attachment of platelets under shear flow conditions. 1,2 VWF is a multimeric plasma glycoprotein composed of functionally distinct types of domains that are either duplicated or triplicated in the following order from the N-terminus: D'-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK. 3, 4 It is the interaction between VWF-A1 domain and the platelet receptor glycoprotein Ib alpha (GPIbα) that initiates primary hemostasis by bringing platelets into close proximity with reactive substrates generated at the site of arterial damage. [5] [6] [7] [8] The clinical significance of this interaction is underscored by the increased bleeding tendencies of individuals who either lack the plasma protein or possess mutations within the A1 domain of VWF. In the latter case, this includes mutations that limit binding (type 2M) or paradoxically enhance interactions (type 2B), both of which are associated with the hereditary bleeding disorder known as von Willebrand disease (VWD). 3, 4 Against this background, structure analyses of native and mutant complexes have provided insights into the nature of the interactions that support adhesion between this receptor-ligand pair and possible mechanisms by which mutations alter this process. The structure reveals a major and minor binding site for GPIbα on the surface of the A1 domain that is bridged by an area of solvated charge interaction. 9, 10 Type 2M mutations, 5 located in or directly adjacent to the larger contact surface, may disrupt electrostatic interactions between this receptor-ligand pair or induce structural changes that reduce GPIbα binding. In contrast, type 2B mutations are clustered in close proximity to the minor site near the termini of the domain and may alter the conformation of a region known as the α1-β2 loop. [9] [10] [11] [12] Consequently, this is thought to provide an essential energetic contribution that augments binding affinity 9 or reduce a steric clash that would impede adhesion. 13 Clinically, this enhanced binding is believed to result in bleeding by permitting VWF multimers with the greatest hemostatic potential to aggregate spontaneously with platelets in blood and ultimately be cleared from the circulation. 3, 4 Although such studies provide insight into mechanism(s) by which mutations associated with VWD may alter binding between platelets and VWF, they cannot account for interactions involving sites outside of the A1 and GPIbα binding domains or external influences such as shear flow that play a role in regulating hemostasis and thrombosis.
14 Indeed, several mechanisms have been identified that may prevent VWF-platelet aggregate formation in the circulation. This includes shielding of VWF-A1 by the adjacent D'D3 domains, 15 the inhibitory effects of the β2-glycoprotein I, 16 and the ability of shear flow to activate the VWF-A1 so that it can then engage GPIbα. 17 Moreover, it has been demonstrated that forces generated by flowing blood can promote the unfolding and elongation of VWF so that it exposes multiple A1 domains. 18 An additional mechanism that has not been fully explored is the contribution that the physicochemical properties of the bond formed between VWF-A1 and GPIbα play in regulating platelet-VWF interactions at sites of vascular injury. Indeed, detailed analyses of the kinetic and mechanical properties of this receptor-ligand pair have yielded insight 6 into the biophysical consequences of the predicted allosteric change associated with type 2B mutations. [19] [20] [21] [22] That said, it remains unclear whether specific properties of the GPIbα-VWF-A1 bond predicted to regulate platelet-VWF interactions correspond with biological reality. [23] [24] [25] In the current study, we address this shortcoming by performing a detailed kinetic analysis of WT and mutant murine GPIbα-VWF-A1 complexes and then validating these observations using transgenic mice harboring modified VWF-A1 domains. We also probe the binding interface using a novel allosteric inhibitor that prevents the formation of key interactions between this receptor-ligand pair. Our data reveal that the physicochemical properties of the distinct regions of contact between this receptor-ligand pair contribute to a composite biophysical signature required for effective hemostasis and arterial thrombus formation.
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Methods
Modeling of murine GPIbα-VWF-A1 complexes
Crystal structures of the human GPIbα-VWF-A1 complex have been described for WT and for the complex formed between the GOF mutations R1306Q and I1309V in VWF-A1 and the platelet type GOF mutation M239V in GPIbα. 9, 10, 13, 26 The human platelet receptor was used as a template for mouse GPIbα. Consensus rotamers with minimal steric clashes were chosen, followed by adjustments to create reasonable van der Waals interactions and H-bonding using COOT (http://www.biop.ox.ac.uk/coot/).
A consensus model of the human receptor-ligand pair was used to build its murine counterpart. This included the double mutant VWF-A1 (I1309V, R1326H)
complex that was based on the human VWF-A1 (R1306Q) mutant complex using the program SWISSMODEL (http://swissmodel.expasy.org/). 10 Figures were created using PYMOL.
Mice
The generation of the VWF R1326H mutant mouse has been previously described. 27 A similar targeting strategy was used to introduce the double mutation I1309V, R1326H
into exon 28 of the murine VWF gene or to substitute in the human A1 domain. VWF deficient mice were purchased from The Jackson Laboratory. All animals were on a C57BL/6J background and kept in a pathogen-free facility. Experiments were performed in accordance to the guidelines set forth by Institutional Animal Care and Use Committee at Columbia University Medical Center.
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Analysis of VWF expression and function
Detection and/or measurement of murine VWF A1-A2-A3 domain transcripts, plasma VWF antigen levels, functional factor VIII levels, and multimer pattern were performed as previously described.
27-30
Platelet adhesion in flow
A parallel-plate flow chamber was used to assess platelet attachment and translocation on surface-immobilized plasma VWF or recombinant VWF-A1 protein. 27 Generation and purification of recombinant proteins were performed as previously described. 20, 26 Citrated whole blood (150 µl) collected via cardiac puncture from anesthetized WT and mutant VWF mice or from healthy human volunteers (venipuncture) was perfused over the immobilized substrates at wall shear rates ranging from 100 s -1 to 1,600 s -1 for 2 min, followed by washing with Tyrode's buffer. The number of platelets attached per unit area and translocation velocities were determined by off-line analysis. For inhibition studies, OS1 peptide was generated and purified as previously described. 31 The inhibitor was added to 1 ml of citrated whole blood 5 minutes prior to perfusing over surfaceimmobilized substrates.
Platelet aggregation
The ability of ristocetin (Chronolog Corporation) to aggregate human platelets in plasma obtained from healthy volunteers or VWF mutant mice was assessed using a Lumi-Aggregometer (model 540 VS, Chronolog Corporation). 32 In brief, citrated whole blood obtained by cardiac puncture from anesthetized mice or collected via venipuncture from healthy volunteers was centrifuged to obtain platelet poor plasma (PPP). Subsequently, 
Tail bleeding assay
Bleeding times were measured in 8-week old mice after amputating 1 cm of the tail tip and then placing the tail in a physiological saline solution (37°C) as previously described.
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Microsphere tethering frequency
The rate of complex formation was evaluated by measuring the frequency of tethering events between surface-immobilized mouse platelets and microspheres coated with a low site density of recombinant WT or mutant VWF-A1. 20, 21 This was determined by observing the number of beads that paused, but did not translocate, at wall shear rates ranging from 10 s -1 to 300 s -1 . This value was then normalized by dividing the number of beads that formed transient tethers by the number of non-interacting beads transported across the field of view in the focal plane of the immobilized platelet substrate.
Estimation of the amount of VWF-A1 coupled to beads was determined using a calibrated microbead system (Flow Cytometry Standards) following manufacturer's instructions. The site density of VWF-A1 on beads was estimated to be ~35 sites/µm 2 .
Dissociation rate constants of transient tethers
The duration of transient tethers was estimated for VWF-A1-coated microspheres interacting with surface-immobilized platelets at wall shear stresses ranging from 0. 5 to Statistical analysis of all other data was determined using unpaired Student's t-test (GraphPad Prism software). Values were considered significant at P < 0.05.
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Results
Structural and functional changes associated with I1309V and R1326H mutations
To determine the interplay between known contact surfaces and to establish the role that the biophysical properties of the GPIbα-VWF-A1 bond play in regulating platelet-VWF interactions, we chose mutations within the major or minor contact interfaces of the murine A1 domain that enhance (I1309V) or disrupt (R1326H) binding.
The I1309V mutation is known to cause type 2B VWD, 33 while the R1326H substitution impairs interactions with mouse GPIbα. 27 Interestingly, several mammalian species including humans have a histidine in lieu of arginine at position 1326 within the A1 domain. 34 Thus, murine VWF is ideal for determining how this particular amino acid substitution alters the biophysical properties of the GPIbα-VWF-A1 bond and its ability to support hemostasis and thrombosis. Models of WT and mutant murine complexes were built to better understand the effect of the mutations on binding ( Figure 1A ). Although crystal structure analyses have yet to identify the exact mechanism by which the I1309V mutation augments adhesion, 9, 13 it is located in the α1-β2 loop adjacent to the type 2B mutation R1306Q. 9, 10 The latter mutation is believed to result in a local conformational change with a re-positioning of residues Q1311 and R1334 that reinforce interactions with human GPIbα. 9 Figure 1B illustrates the position of residue 1309 in the context of the complex formed with murine GPIbα and the augmentation in binding that occurs upon re-positioning of residues Q1311 and R1334.
To understand how these mutations affect adhesion under flow conditions, we generated recombinant murine VWF-A1 (rVWF-A1) proteins containing the R1326H 1 3 and I1309V substitutions and determined their ability to support mouse platelet interactions when surface-immobilized in a parallel plate flow system. 27 The R1326H mutation impaired mouse platelet accumulation and increased translocation velocity ~13-fold as compared to WT rVWF-A1 ( Figure 1C-D) . In contrast, the I1309V mutation decreased translocation velocity ~5-fold and greatly augmented platelet accumulation.
Strikingly, rVWF-A1 containing both amino acid substitutions yielded an adhesive phenotype comparable to WT.
I1309V and R1326H mutations differentially alter bond formation and dissociation
To determine whether the biophysical properties of rVWF-A1 expressing both mutations truly reflect that of the WT complex, we analyzed the formation and dissociation of transient adhesive events, known as tether bonds, that occur when flowing rVWF-A1-coated microspheres transiently interact with GPIbα expressed on surfaceimmobilized mouse platelets. 20, 21 On-rate was determined by evaluating the frequency with which microspheres interacted with surface-immobilized mouse platelets at various wall shear rates. Whereas the I1309V mutation enhanced the rate of association ~3.5-fold, this was abolished when combined with the R1326H substitution ( Figure 2A ). In fact, murine rVWF-A1 possessing the double mutation displayed a rate of association that more closely resembled the WT complex with a maximal tethering frequency at a wall shear rate of 85 s -1 .
The effects of the mutations on the kinetics of dissociation (k off ) were determined measuring the lifetime of tether bonds and their response to an applied force. 20, 21 We
previously showed the utility of this system for assessing the biophysical properties of the interaction between human GPIbα and rVWF-A1. Moreover, the use of microspheres with a uniform size and shape permits the calculation of the amount of shear force acting on the tether bond. As previously observed for the human complex, the distribution of interaction times indicated that the majority of WT and mutant tether bonds fit a straight line, the regressed slope of which corresponded to -k off ( Figure 2B-E Figure   2F and Table 1 ). Whereas the major effect of the I1309V substitution was to prolong the lifetime of the tether bond (6-fold), R1326H shortened its duration (2.5-fold). However, the kinetic (k 0 off ) and mechanical (σ) properties of rVWF-A1 bearing both mutations were nearly identical to that of the native complex.
Hemostatic and thrombotic properties of murine VWF possessing mutant A1 domains 1 5 To determine whether the predictions based on biophysical studies truly have biological relevance, we generated knock-in mice that express either the R1326H (VWF  R1326H ) mutation alone 27 or in combination with I1309V (VWF I1309V, R1326H ) (supplemental Figure 1A-C) . VWF gene transcription, multimer pattern, antigen levels as well as factor VIII function and platelet counts were similar to WT littermates (supplemental Figure   1D -H). Consistent with the reduction in bond lifetime and impaired adhesion, animals expressing the R1326H mutation had prolonged tail bleeding times and a diminished capacity to form arterial thrombi ( Figure 3A-B) . In fact, VWF R1326H mice possessed a phenotype similar to that observed for mice lacking this plasma protein (VWF KO ).
Remarkably, the additional incorporation of the I1309V mutation corrected the observed perturbations in platelet-VWF interactions. Not only did VWF-A1 double mutant animals have hemostatic properties similar to WT littermates, but also laser-induced thrombi were comparable in size to mice possessing the WT plasma protein ( Figure 3A- B). Direct evidence that plasma VWF I1309V, R1326H has adhesive properties equivalent to its WT counterpart is demonstrated by its ability to support mouse platelet accumulation and translocation velocities at similar levels ( Figure 3C-D) . This was not the case for plasma VWF R1326H which impaired platelet adhesion and yielded a ~3-fold increase in translocation velocity. These data support a close association between the lifetime of the GPIbα-VWF-A1 bond and the ability of these hemostatic elements to support critical biological processes.
Targeting the major binding interface between human GPIbα and VWF-A1 1 6 Given the importance of the major contact site in supporting mouse platelet-VWF interactions in vivo, we next explored the therapeutic utility of targeting this region in the human complex. This was accomplished by using a novel cyclic peptide, termed OS1, which was isolated from a cysteine-constrained phage display library. 31 It interacts with the curved concave face of the GPIbα leucine-rich repeat, 37 stabilizing a conformation of a regulatory loop known as the β-switch 10 so that it prevents the formation of electrostatic interactions essential for binding to the VWF-A1 domain ( Figure 4A ). However, the To directly test the ability of OS1 to prevent human platelet-mediated arterial thrombosis, we generated an animal in which the majority of the murine A1 domain was replaced with its human counterpart (supplemental Figure 2A-B) . VWF gene transcription, multimer pattern, antigen levels and platelet counts in VWF HA1 mice were similar to WT littermate controls (supplemental Figure 2C-F) . In addition, animals containing the human VWF-A1 domain manifested impaired platelet-vessel wall interactions that resulted in a prolongation in tail bleeding time as well as a reduction in thrombus size in laser-injured arterioles ( Figure 5A -B). Consistent with these observations was the inability of surface-immobilized plasma VWF HA1 to support mouse platelet accumulation in flow ( Figure 5C ). In the presence of human platelets, however, 1 7 VWF HA1 mice formed large and often occlusive thrombi in laser-injured arterioles of nearly identical size to that observed in their VWF R1326H counterparts ( Figure 5D ).
Accumulation of human platelets on surface-immobilized plasma VWF from either animal was also comparable ( Figure 5E ). Yet, only plasma VWF from mice possessing the human VWF-A1 domain supported ristocetin-induced platelet agglutination / aggregation of human platelets demonstrating that the R1326H mutation in murine VWF-A1 was not sufficient to support this process ( Figure 5F ). Importantly, the OS1 peptide was able to impair human platelet accumulation on surface-immobilized plasma VWF HA1 and inhibited ristocetin-induced platelet agglutination / aggregation ( Figure 6A-B) .
Moreover, human platelet-mediated thrombus formation in arterioles of VWF HA1 mice was reduced by >80% in the presence of the inhibitor ( Figure 6C ). The data demonstrate the potential therapeutic utility in targeting the major contact interface formed between the human GPIbα-VWF-A1 complex.
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Discussion
Detailed structural and biophysical analyses of small regions of contact between GPIbα and VWF-A1 have yielded tremendous insight into the relationship between forcelifetime-and-chemistry of an interaction critical for supporting hemostasis and thrombosis.
Here, we have taken a unique approach to better understand the role that the kinetic properties of the contact surfaces formed between this receptor-ligand pair play in supporting these biologically relevant processes. By generating animals with mutations contained within the major and minor binding sites of murine VWF-A1 that either reduce or enhance attachment to GPIbα, we provide the first in vivo evidence that bond lifetime does play an important role in regulating platelet-VWF interactions at sites of arterial injury.
To determine whether data obtained using a murine-based system were applicable to the human receptor-ligand pair, we first measured the kinetic properties of the murine GPIbα-VWF-A1 bond and its response to an applied force. Values for the intrinsic offrate were similar between the species (k 0 off values of 3.05 ± 0.55 s -1 and 3.45 ± 0.37 s -1 for the mouse and human complex, respectively). However, the reactive compliance (σ) for the WT murine complex was ~1.5-fold higher than for its human counterpart (0.028 ± 0.001 nm versus 0.018 ± 0.002 nm, respectively), suggesting that the interaction between the murine receptor-ligand pair may be slightly more prone to dissociate upon the application of hydrodynamic force. The effects of the I1309V substitution mirrored that of the human rVWF-A1 mutant 20 , including the reduced requirement for shear flow to promote GPIbα interactions with VWF-A1 and a prolongation in bond lifetime.
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Surprisingly, the observed alterations in adhesion did not persist when this mutation was combined with R1326H. In fact, the biophysical properties of the double mutant bond more closely resembled that of the native complex. These observations led us to predict that murine plasma VWF I1309V, R1326H should possess hemostatic and thrombotic properties similar to the native plasma protein if bond lifetime plays an important role in these processes. This was borne out by the fact that I1309V, R1326H double knock-in mice had tail bleeding times and formed arterial thrombi of similar size to that observed for WT littermates. Based on these observations we conclude that the major and minor contact interfaces not only contribute to a biophysical signature well suited for supporting platelet-VWF interactions under the hydrodynamic conditions encountered in the arterial circulation, but also that they must be maintained within strict limits in order to optimize platelet accumulation at sites of vascular injury.
Although the precise mechanism(s) by which the I1309V mutation augments binding remains controversial, 9,13 its pronounced effects on the biophysical properties of the murine GPIbα-VWF-A1 bond made it suitable for gaining insight into the relationship between bond lifetime and the requirement for shear flow to initiate platelet attachment to VWF. It is well known that the application of a specific level of shear is essential to achieve optimal adhesion between GPIbα and VWF-A1 (termed the shear threshold effect). 20 Shear-induced forces are thought to influence the GPIbα-VWF-A1 bond in two ways. As the applied force increases from low levels, the bond lifetime increases until it is of sufficient duration to promote effective interactions between platelets and VWF (termed a catch bond). [38] [39] [40] It is only when force exceeds the critical value does the lifetime shorten and the bond ultimately rupture (termed a slip bond) in 2 0 accordance with Bell's model. 35 However, this concept has been challenged in a study suggesting that the shear threshold effect may be due to a transition of a slip bond from a low to high affinity state in response to a force-induced conformation change in the complex. 41 Despite these conflicting views, our data suggest that the ability of the I1309V mutation to prolong the lifetime of the GPIbα-VWF-A1 bond beyond that of the native complex is essential for promoting platelet-VWF interactions at low flow states.
Moreover, the process is reliant on the biophysical properties of the major contact interface. In the presence of the R1326H substitution, the I1039V mutation could no longer abolish the requirement for shear flow to support the tethering of murine rVWF-A1 coated beads to mouse GPIbα, nor slow mouse platelet translocation velocities and augment platelet attachment to surface immobilized VWF-A1 containing the double mutation.
It is important to note that the ability to prolong the lifetime of the GPIbα-VWF-A1 bond is not unique to type 2B mutations as it has also been reported for snake venoms. This is best exemplified by the ability of botrocetin, a component of Bothrops jararaca venom, to promote platelet-VWF aggregation in plasma as well as contribute to the loss of VWF multimers and platelets from the blood. 42 Interestingly, we have shown that the major effect of botrocetin is to increase the bond lifetime two-fold for both human and mouse complexes without affecting the on-rate. 26 This did not involve allosteric changes in GPIbα or VWF-A1, but relied on the ability of the venom protein to form a biological clasp that prolonged their embrace. These results further support our current observations that the lifetime of the GPIbα-VWF-A1 bond contributes significantly to promoting effective platelet-VWF interactions at sites of arterial injury.
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There has been much speculation on whether one or both of the identified binding surfaces between GPIbα and VWF-A1 could be targets for the prevention or treatment of thrombosis. 43 Our current study helps clarify this issue. We demonstrate that a cyclic peptide (OS1) proven to alter the conformation of GPIbα so that is incapable of forming several key interactions with the major binding interface of VWF-A1 significantly reduced human platelet-mediated thrombus formation in laser-injured arterioles of VWF HA1 mice. Thus, the development of such agents that can alter specific interactions between this receptor-ligand pair offers a powerful approach to reducing arterial thrombosis.
In summary, animals bearing specific mutations in a protein critical to promoting Data are the mean ± standard deviation. **P < 0.001 relative to control. 
